A novel nasal powder formulation of glucagon: toxicology studies in animal models

Table 4 Achieved powder dose levels of GNP per animal

Group number	Group designation	Targeted powder dose (mg)	Achieved average powder dose (mg)	% efficiency
1	Placebo control	40.0	33.0^a	82.5
1	Placebo control	40.0	37.1^b	92.8
3	Low dose	20.0	18.9^a	94.5
3	Low dose	20.0	19.9^b	99.5
4	High dose	40.0	36.8^a	92.0
4	High dose	40.0	39.6^b	99.0

^aCalculated using all values from the entire study including discharge weights obtained before implementation of a device wiping procedure to correct the adverse effect of device-related electrostatic charge on the analytical balance
^bCalculated using values beginning April 8, 2011 (equivalent to study Day 10, 11, or 12 depending on the dog) after instituting a device wiping procedure to remove electrostatic charge and thus resulting in accurate and expected discharge weights

ISSN: 2050-6511